Credo's Eight-Quarter Beat Streak Fails to Calm Customer Concentration Fears
Read source articleWhat happened
Credo has now beaten earnings estimates for eight consecutive quarters and more than doubled revenue, yet the stock continues to sink, reflecting a widening gap between fundamental momentum and market confidence. The latest filings show two direct customers still account for 43% and 28% of revenue, with accounts receivable concentration even higher at 57% and 28%, leaving demand hostage to a handful of hyperscaler purchase orders. Gross margin fell to 64.5% from 67.4%, inventory climbed to $313.1 million, and non-cancelable purchase obligations reached $222.2 million, signaling that the cost of growth is rising. The company's much-hyped optical products have yet to appear as a material revenue line, and the $1.251 billion DustPhotonics acquisition has added nearly $1 billion in goodwill without yet proving commercial scale. At $182, the stock already prices sustained AEC growth, successful optical monetization, and stable margins, leaving no cushion if any single customer pauses or delays orders.
Implication
Over the next 6–18 months, investor returns hinge on whether Credo can prove optical products are contributing meaningful revenue and whether hyperscaler demand holds without margin deterioration. If diversification fails and a top customer pauses, the stock could fall toward $145; if optical volume ramps and margins stabilize, a re-rate toward $220 is possible. Until those proofs arrive, the risk/reward remains balanced but not asymmetric, and existing holders should use strength to reduce exposure rather than add at current levels.
Thesis delta
The news article reinforces our existing WAIT thesis by highlighting that eight straight earnings beats have not reversed the stock's decline, confirming that the market is now focused on revenue quality, not raw growth. Our view remains unchanged: Credo's concentration risk and unproven optical transition justify a neutral stance until filings demonstrate customer diversification and stable margins. We maintain our attractive entry near $155 and trim target above $215, with no evidence yet to upgrade the rating.
Confidence
Medium-High